Browsing Tag
Eisai
15 posts
Catalyst Pharmaceuticals (CPRX) agrees $4.1bn buyout as Angelini Pharma plans to enter US rare disease market
Angelini Pharma will pay $4.1 billion for Catalyst Pharmaceuticals at $31.50 a share, but CPRX closed at $31.10. The premium sits in the strategy, not the price.
Eisai and Shanghai Henlius Biotech enter Japan-focused licensing pact for serplulimab as PD-1 competition tightens
Discover how Eisai Co., Ltd.’s serplulimab licensing deal with Henlius could reshape Japan’s PD-1 oncology market and investor expectations.
Leqembi gains traction in China as commercial insurance innovative drug list expands access for Alzheimer’s patients
Leqembi gains commercial insurance status in China, opening doors for Alzheimer’s patients and transforming access. Find out what this means for BioArctic AB and Eisai.
Leqembi UK approval: BioArctic, Eisai win MHRA nod for once-monthly Alzheimer’s treatment
BioArctic’s Leqembi now approved for monthly IV use in UK Alzheimer’s patients. Find out what this means for long-term treatment worldwide.
Eisai’s etalanetug earns FDA Fast Track status, signaling new hope in Alzheimer’s therapy
Eisai’s etalanetug gets FDA Fast Track for Alzheimer’s, signaling a major shift toward tau-targeting therapies. Find out what this means for investors.
CHMP backs Lecanemab again for early Alzheimer’s as EC reviews approval
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has reaffirmed its positive opinion on…
FDA approves Leqembi maintenance dosing for early Alzheimer’s treatment
The U.S. Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi (lecanemab-irmb), an…
Breakthrough liver cancer treatment: Merck’s new drug combo slashes disease progression risk by 34%
Merck & Co., Inc. (known as MSD outside the United States and Canada) and Eisai Co., Ltd. have…
Eisai initiates rolling submission for Leqembi autoinjector BLA to FDA
BioArctic AB’s partner Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S.…
Biogen reprioritizes Alzheimer’s disease resources, discontinues ADUHELM development
Biogen Inc. (Nasdaq: BIIB), a leading pharmaceutical company, today announced a strategic reprioritization of its resources in Alzheimer’s…